Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective

TY - JOUR

T1 - Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease

T2 - A multicenter perspective

AU - the SCD Arginine Study Group and PECARN

AU - Rees, Chris A.

AU - Brousseau, David C.

AU - Ahmad, Fahd A.

AU - Bennett, Jonathan

AU - Bhatt, Seema

AU - Bogie, Amanda

AU - Brown, Kathleen M.

AU - Casper, T. Charles

AU - Chapman, Laura L.

AU - Chumpitazi, Corrie E.

AU - Cohen, Daniel M.

AU - Dampier, Carlton

AU - Ellison, Angela M.

AU - Grasemann, Hartmut

AU - Hickey, Robert W.

AU - Hsu, Lewis L.

AU - Lane, Peter A.

AU - Bakshi, Nitya

AU - Leibovich, Sara

AU - Patil, Prabhumallikarjun

AU - Powell, Elizabeth C.

AU - Richards, Rachel

AU - Sarnaik, Syana

AU - Weiner, Debra L.

AU - Morris, Claudia R.

N1 - Funding Information: This study was supported by the NIH/NHLBI under award number R34HL122557 (to CRM), and in part by NIH/NCCIH K24AT009893 (to CRM) and the Pediatric Emergency Care Applied Research Network (PECARN), supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS), in the Maternal and Child Health Bureau (MCHB), under the Emergency Medical Services for Children (EMSC) program through the following cooperative agreements: DCC‐University of Utah, GLEMSCRN‐Nationwide Children's Hospital, HOMERUN‐Cincinnati Children's Hospital Medical Center, PEMNEWS‐Columbia University Medical Center, PRIME‐University of California at Davis Medical Center, CHaMP node‐ State University of New York at Buffalo, WPEMR‐ Seattle Children's Hospital, and SPARC‐ Rhode Island Hospital/Hasbro Children's Hospital. NB received funding from the NIH/NHLBI under award number 1K23HL140142 and 1K23HL140142‐03S1, from the Doris Duke Charitable Foundation COVID19 Fund to Retain Clinical Scientists‐ PeRSEVERE Program at Emory University School of Medicine, and the Georgia Clinical and Translational Science Alliance under award UL1‐TR002378. The funders had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation, review, approval of the manuscript, or decision to submit the manuscript for publication. Funding Information: Doris Duke Charitable Foundation; National Institutes of Health, Grant/Award Numbers: 1K23HL140142, 1K23HL140142‐03S1, K24AT009893, R34HL122557; Pediatric Emergency Care Applied Research Network (PECARN), supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS), in the Maternal and Child Health Bureau (MCHB), under the Emergency Medical Services for Children (EMSC); PeRSEVERE Program at Emory University School of Medicine, and the Georgia Clinical and Translational Science Alliance, Grant/Award Number: UL1‐TR002378 Funding information

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85136728385&partnerID=8YFLogxK

U2 - 10.1002/ajh.26696

DO - 10.1002/ajh.26696

M3 - Letter

C2 - 36054566

AN - SCOPUS:85136728385

SN - 0361-8609

VL - 97

SP - E412-E415

JO - American journal of hematology

JF - American journal of hematology

IS - 11

ER -